International, Multicenter, Study of a Twenty-Eight Week,Open-Label, Titrated Oral Lixivaptan Administration inPatients with Chronic Hyponatremia: Extension to StudiesCK-LX3401, 3405, and 3430

CARDIOKINE0 个研究点目标入组 150 人开始时间: 待定最近更新: 2021年11月24日

试验速览

阶段: 3 期
状态: 已完成
发起方
入组人数: 150

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

入选标准

•1. Age greater than or equal to 18 years
•2. Ability to provide informed consent or assent
•Note: Patients must have the ability to clearly indicate their own informed consent/ assent for participation in this study. Sole consent by legal guardian will not be considered acceptable; however, signature of the consent by a guardian on behalf of a consenting patient incapable of affixing his or her own signature may be acceptable (e.g., high spinal cord injury). Consent by a legal guardian on behalf of patients with diminished capacity (e.g., stable schizophrenia, encephalopathy or senile dementia) must be made with the patient?s assent and must comply with the requirements of the site?s Independent Ethics Committee (IEC) or Institutional Review Board (IRB). Special arrangements for such patient?s care and supervision must be outlined to the site?s IRB/IEC. Patients with evidence of significant neurological symptoms attributable to hyponatremia, should use standard therapies to correct the hyponatremia. This correction must at a minimum improve cognition to the point where a valid informed consent may be given and where the likelihood of seizures or other danger has been mitigated.
•3. Prior participation in a lixivaptan hyponatremia trial with evidence of continued need or desire for therapy. Patients must have demonstrated acceptable study drug compliance ( >70% of prescribed drug taken) and adherence to study procedures in the parent trial. Patients may be eligible if after Principal Investigator (PI) consultation with the Medical Monitor they have been withdrawn from the previous study due to a perceived lack of treatment effect requiring the use of intravenous (IV) saline infusion or alternate excluded therapy. The patient?s therapeutic nonresponse should be appropriately documented. No effort to unblind the patient?s previous treatment assignment should be undertaken with the sole intent of determining whether a nonresponse resulted from the patient?s receiving placebo or to their condition?s resistance to lixivaptan. While the ?need for therapy? in mild hyponatremia (sodium >129 mEq/L [mmol/L]), or even in the lower ranges of normal (sodium 135 to140 mEq/L [mmol/L]) is not established, based on the PI?s and patient?s agreement as to therapy?s desirability, enrollment in this study is possible. Justification for enrollment of patients whose sodium at entry is in the normal range must be given to, and accepted by, the Medical Monitor for the study.

排除标准

•1. A current medical condition where long-term treatment with an aquaretic agent may present an undue risk to the patient
•For example:
•a. Women who are pregnant, breast feeding, or of childbearing potential who are not using acceptable contraceptive methods.
•b. Conditions limiting access to water (e.g., bedridden and noncommunicative)
•c. Severely disordered thirst (e.g., psychogenic polydipsia, hydrophobia or anorexia)
•d. Patients with urinary outflow obstruction (hydronephrosis is a risk unless
•catheterized)
•e. Significant hypotension (systolic blood pressure 90 mmHg) or pulmonary artery hypertension (fragile intravascular fluid balance)
•f. Known allergy to any vasopressin antagonist or any condition for which treatment with a vasopressin antagonist may present undue risk to the patient.
•2. Hyponatremia which is acute, reversible, artifactual or due to conditions not associated with vasopressin excess or likely to respond to aquaretic therapy.
•Note: By definition all patients entering in the preceding trials had chronic, non-reversible, nonartifactual hyponatremia. It is plausible that between the patient?s completion of these trials one or more of these factors may now exist. In such circumstances, the patient should not be enrolled. For example:
•a. Hyponatremia in hypovolemic states Hypovolemic hyponatremia is defined as the presence of clinical and historical evidence of extracellular fluid volume depletion. Examples of clinical hypovolemic hyponatremia states include conditions where restoration of plasma volume results in correction and maintenance of normal plasma sodium concentration or those associated with critically low central venous pressure (5 cm H2O) or pulmonary capillary wedge pressure (5 mmHg); but do not include conditions such as CHF or cirrhosis where there is evidence of fluid overload (e.g., ascites or dependent edema) despite an inappropriate homeostatic response to perceived intravascular volume depletion.
•b. Acute and transient Hyponatremia Associated with head/brain trauma or post-operative pain, acute water intoxication, polydipsia, intravenous (IV) fluid administration, isolated pulmonary infection
•c. Artifactual Hyponatremia As due to hyperglycemia or hyperlipidemia
•d. Hyponatremia in states of severe renal impairment (creatinine 3.0
•3. Hyponatremia due to reversible medical condition or therapy
•For example:
•a. Severe, uncontrolled hypothyroidism or uncontrolled hypoadrenalism.
•b. Use of a medication, known to be associated with hyponatremia, which may be safely and easily substituted for another class.
•4. Conditions associated with an independent imminent risk of morbidity and mortality.
•Patients whose prognosis suggests a life expectancy of at least 6 months are eligible; however, if the prognosis suggests a significant likelihood of a morbid or mortal event within the expected duration of the study, this information should be collected at time of enrollment.

研究者

发起方

CARDIOKINE

相似试验

已完成

不适用

International, Multicenter Study of a Twenty-eight Week, Open-label, Titrated Oral Lixivaptan Administration in Patients With Chronic Hyponatremia: Extension to Studies CK-LX3401, 3405, and 3430

PER-068-10Cardiokine Biopharma, LLC,

进行中（未招募）

不适用

International, multi-center, study of a twenty-eight week, open-label, titrated oral lixivaptan administration in patients with chronic hyponatremia: extension to studies CK-LX3401, 3405, and 3430 - OleChronic hyponatraemiaMedDRA version: 12.1Level: LLTClassification code 10021036Term: Hyponatraemia

EUCTR2009-016371-30-DECardiokine Biopharma LLC150

进行中（未招募）

不适用

EUCTR2009-016371-30-BECardiokine Biopharma LLC150

进行中（未招募）

不适用

EUCTR2009-016371-30-CZCardiokine Biopharma LLC150

进行中（未招募）

不适用

International, Multicenter, Study of One-Year, Open-Label, Titrated Oral Tolvaptan Tablet Administration in Patients With Chronic Hyponatremia Extention to Studies 156-02-235 and 156-03-238 to Asses One-Year Safety.

EUCTR2004-000452-16-ITOTSUKA MARYLAND RESEARCH INSTITUTE400